Thus, although anti-PD-1 therapy induces Tfh-cell, plasmablast and CXCL13 responses, it reduces the sialylation of anti-hemagglutinin antibodies at baseline and following vaccination, affecting the quality of influenza-specific antibodies (Fig. 2). Here, PDCD1 is linked to influenza.